#peptides

Health Affairs Forefront analysis by Mengyuan Fu, Joseph S. Ross, Ngoc-Trang Adrienne H. Nguyen, and Reshma Ramachandran of the FDA Pharmacy Compounding Advisory Committee's July 2026 vote to add six unapproved peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the 503A Bulks List despite FDA scientists finding insufficient evidence of benefit, safety, or manufacturing quality, and documents financial conflicts of interest among the voting committee members.

Peter Attia lays out a five-question framework (mechanism, human evidence, safety/dosing, risk-benefit, better-characterized alternatives) for evaluating any peptide, then applies it to BPC-157 and CJC-1295 to show why gray-market peptide claims tend to expand over time instead of narrowing, unlike legitimate drug development.

via #403 ‒ Peptides: separating scientific promise from marketing hype